| 摘要 |
Disclosed is a use of a compound targeting ApoCIII in the manufacture of a medicament for a) treating, preventing, delaying or ameliorating pancreatitis in an animal; b) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby preventing, delaying or ameliorating a cardiovascular disease, disorder, condition or symptom thereof or onset of a cardiovascular disease, disorder, condition or symptom thereof in an animal; c) increasing HDL levels and/or improving the ratio of TG to HDL in an animal thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal; and/or d) treating, preventing, delaying or ameliorating chylomicronemia, wherein the compound is capable of inhibiting apolipoprotein C-III. |
